The role of inhibitor of YAP1 in triple negative breast cancer with taxol‐based chemoresistance

Abstract

The Triple negative breast cancer (TNBC) associates with high aggressive clinical behavior, and the taxol‐based chemo‐resistance remains a big TNBC therapeutic problem to be solved. Verteporfin, a small molecular The Yes‐associated protein 1 (YAP1) inhibitor, is little known to be a anti‐tumor drug for TNBC. Our data showed that the YAP1 expression was associated with early relapse in tissue sample of patients with TNBC taxol chemoresistance (P<0.001). Verteporfin, the inhibitor of YAP1, reduced migration and enhanced apoptosis or autophagy of taxol resistance MDA‐MB‐231 cell line in vitro. Knockdown of YAP1 increased EMT response in taxol resistant TNBC cell line. In the in vivo experiment, we found that Verteporfin is able to shrink the tumor weight and volume and decreased the Ki67 expression in taxol‐resistance mouse model. Our results provide the evidence for Verteporfin could be a chemo‐sensitizer for TNBC patients with taxol‐based treatment.

This article is protected by copyright. All rights reserved.

https://ift.tt/2S6C3Xb